Key result
Novel NO-donor aspirin-like molecules demonstrated anti-inflammatory efficacy comparable to aspirin in rats, but with significantly reduced gastrotoxicity, alongside antiplatelet and vasodilatory properties.
Why the study?
Do nitrooxy-acyl derivatives of salicylic acid provide anti-inflammatory and antiplatelet effects with reduced gastrotoxicity compared to aspirin in preclinical models?
Do nitrooxy-acyl derivatives of salicylic acid provide anti-inflammatory and antiplatelet effects with reduced gastrotoxicity compared to aspirin in preclinical models?
Nitrooxy-acyl derivatives of salicylic acid demonstrate anti-inflammatory, antiplatelet, and vasorelaxant properties with potentially reduced gastrointestinal toxicity compared to aspirin in preclinical models.
No takes yet. Share an insight, caveat, or question.
May support NO-aspirin hybrid development; leaves open human gastroprotection and efficacy.
Lazzarato et al. (2008) studied Inflammation, gastrotoxicity, platelet aggregation. NO-donor aspirin-like molecules (nitrooxy-acyl derivatives of salicylic acid) vs. Aspirin and vehicle was evaluated on Carrageenan-induced paw edema reduction and gastric lesion index. Novel NO-donor aspirin-like molecules demonstrated anti-inflammatory efficacy comparable to aspirin in rats, but with significantly reduced gastrotoxicity, alongside antiplatelet and vasodilatory properties.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: